Proteomics

Case Western Reserve University, Cleveland OH

Investigators

Linked publications, trials & patents

Abstract

PROTEOMICS SHARED RESOURCE PROJECT SUMMARY/ABSTRACT The Case Comprehensive Cancer Center (Case CCC) Proteomics Shared Resource, with facilities and staff at Cleveland Clinic and CWRU sites, provides cutting-edge proteomic and small molecule analysis services and develops innovative technologies to advance cancer research as a key part of the Case CCC community. With extensive instrumentation, expert staff, and structured administrative leadership from the Case CCC, the Shared Resource facilitates impactful science through user service modes ranging from customizable collaboration to high throughput service. Recent advances highlighting the shared resource's impact in the renewal proposal include novel bioinformatics tools for reliable kinase inference from phosphoproteomic data. The novel RoKAI software leverages context-specific kinase-substrate interactions to reveal cellular rewiring in disease. Additionally, the Shared Resource has pioneered techniques in structural mass spectrometry to map protein dynamics and drug binding sites enabling mechanistic studies revealing the induced fit binding mechanism of a critical inflammation target. Other recent scientific highlights include the use of protein interactome and protein phosphorylation analysis to enable cancer investigators to interrogate complex alterations in cellular pathways that mediate transformation or resistance to therapy. The Shared Resource's sites also provide typical services like protein ID, PTM characterization, quantitative proteomics, interactome analysis, and metabolomics. In the current funding cycle, 342 investigators, 38% of whom were Case CCC members, accounting for 51% of total usage, from all 6 of the Case CCC research programs utilized the SR. With significant institutional investment in infrastructure and staff, the shared resource exemplifies an exceptional shared resource that enables impactful research. It has secured multiple new instruments at the state of the art in the recent period thought institutional investment and the award of NIH/S10 grants and will continue expansion consistent with user and science needs. Its commitment to technology innovation and interactive collaboration encourages excellent science and aligns with that expected of an ideal NCI-funded P30 Shared Resource. Goals in the next cycle are to expand capabilities in single cell analysis with a target of 3,000 proteins detected per cell and new MS systems that provide near full proteome coverage (3x current levels) to fully leverage our systems biology tool improvements. Further, new trifluoromethylation footprinting methods to be applied in the coming grant period will achieve single residue protein resolution for prosecuting Case CCC structural biology projects.